nach oben

Archives of Virology

Erschienen in:

01.01.2015 | Original Article

Comparison of two immunoassays for quantification of hepatitis B surface antigen in Chinese patients with concomitant hepatitis B surface antigen and hepatitis B surface antibodies

verfasst von: Weiwei Liu, Yao Hu, Yannan Yang, Tingting Hu, Xinyu Wang

Erschienen in: Archives of Virology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Two commercial quantitative immunoassay platforms are currently available for the detection of hepatitis B surface antigen (HBsAg) within a wide range of concentrations: the Architect HBsAg assay and the Elecsys HBsAg II. However, there are limited data concerning their performance in patients who are positive for both HBsAg and anti-HBs antibodies. In the present study, 127 serum samples from Chinese patients with hepatitis B carrying both HBsAg and anti-HBs antibodies were analyzed. HBsAg levels measured in parallel using the Elecsys HBsAg II and Architect HBsAg assay were compared. There was a significant correlation between HBsAg levels measured by Elecsys HBsAg II and Architect HBsAg assay (correlation coefficient, r = 0.992, P < 0.05). Bland-Altman analysis indicated only minor discordance between the methods (mean difference between Elecsys HBsAg II and Architect HBsAg assay, −0.02 log₁₀ IU/ml; 95 % confidence interval, −0.40–0.37 log₁₀ IU/ml). In conclusion, the results of the quantitative Elecsys HBsAg II were highly correlated with those of the Architect HBsAg assay in patients carrying both HBsAg and anti-HBs antibodies, but differences were observed between the platforms in samples with low HBsAg levels.

Li MR, Xi HL, Wang QH, Hou FQ, Huo N, Zhang XX, Li F, Xu XY (2014) Kinetics and prediction of HBsAg loss during long-term therapy with nucleos(t)ide analogues of different potency in patients with chronic hepatitis B. PLoS ONE 9(6):e98476PubMedCentralPubMedCrossRef

Ke W, Liu L, Zhang C, Ye X, Gao Y, Zhou S, Yang Y (2014) Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. PLoS ONE 9(6):e98865PubMedCentralPubMedCrossRef

Dienstag JL (2008) Hepatitis B virus infection. N Engl J Med 359:1486–1500PubMedCrossRef

Wursthorn K, Lutgehetmann M, Dandri M (2006) Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 44:675–684PubMedCrossRef

Yang R, Cong X, Xu Z, Xu D, Huang W, Maertens R, Wei L (2010) INNO-LiPA HBV genotyping is highly consistent with direct sequencing and sensitive in detecting B/C mixed genotype infection in Chinese chronic hepatitis B patients and asymptomatic HBV carriers. Clin Chim Acta 411:1951–1956PubMedCrossRef

Yao JL (1996) Perinatal transmission of hepatitis B virus infection and vaccination in China. Gut 38(Suppl 2):S37–S38PubMedCentralPubMedCrossRef

Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y (2009) Epidemiological serosurvey of hepatitis B in China–declining HBV prevalence due to hepatitis B vaccination. Vaccine 27:6550–6557PubMedCrossRef

Zhang YM, Yang YD, Jia HY, Zeng LY, Yu W, Zhou N, Li LJ (2014) HBsAg levels in HBeAg-positive chronic hepatitis B patients with different immune conditions. World J Gastroenterol 20(15):4407–4413PubMedCentralPubMedCrossRef

European Association for the Study of the Liver (2009) EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 50:227–242CrossRef

10.

Bowden S (2006) Serological and molecular diagnosis. Semin Liver Dis 26:97–103PubMedCrossRef

11.

Hatzakis A, Magiorkinis E, Haida C (2006) HBV virological assessment. J Hepatol 44(1 Suppl):S71–S76PubMedCrossRef

12.

Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M (2010) Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 51:1933–1944PubMedCrossRef

13.

Moucari R, Marcellin P (2011) Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B. Liver Int 31:122–128PubMedCrossRef

14.

Werle-Lapostolle B, Bowden S, Locarnini S (2004) Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126:1750–1758PubMedCrossRef

15.

Marcellin P, Asselah T, Boyer N (2005) Treatment of chronic hepatitis B. J Viral Hepat 12:333–335PubMedCrossRef

16.

Chu CM, Liaw YF (2006) Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 26:142–152PubMedCrossRef

17.

Moucari R, Mackiewicz V, Lada O (2009) Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 49:1151–1157PubMedCrossRef

18.

Brunetto MR, Moriconi F, Bonino F (2009) Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 49:1141–1150PubMedCrossRef

19.

Chan HL, Wong VW, Tse AM (2007) Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 5:1462–1468PubMedCrossRef

20.

Chan HL, Wong VW, Chim AM, Chan HY, Wong GL, Sung JJ (2010) Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther 32:1323–1331PubMedCrossRef

21.

Deguchi M, Yamashita N, Kagita M (2004) Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 115:217–222PubMedCrossRef

22.

Kohno H, Inoue T, Tsuda F, Okamoto H, Akahane Y (1996) Mutations in the envelope gene of hepatitis B virus variants co-occurring with antibody to surface antigen in sera from patients with chronic hepatitis B. J Gen Virol 77:1825–1831PubMedCrossRef

23.

Mimms L (1995) Hepatitis B virus escape mutants: pushing the envelope of chronic hepatitis B virus infection. Hepatology 21:884–887PubMed

24.

Zhang JM, Xu Y, Wang XY, Yin YK, Wu XH, Weng XH, Lu M (2007) Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection. Clin Infect Dis 44:1161–1169PubMedCrossRef

25.

Lada O, Benhamou Y, Poynard T, Thibault V (2006) Coexistence of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of “a” determinant variants. J Virol 80:2968–2975PubMedCentralPubMedCrossRef

26.

Colson P, Borentain P, Motte A, Henry M, Moal V, Botta- Fridlund D, Tamalet C, Gerolami R (2007) Clinical and virological significance of the co-existence of HBsAg and anti-HBs antibodies in hepatitis B chronic carriers. Virology 367:30–40PubMedCrossRef

27.

Liu W, Hu T, Wang X (2012) Coexistence of hepatitis B surface antigen and anti-HBs in Chinese chronic hepatitis B virus patients relating to genotype C and mutations in the S and P gene reverse transcriptase region. Arch Virol 157(4):627–634PubMedCrossRef

28.

Galli C, Orlandini E, Penzo L (2008) What is the role of serology for the study of chronic hepatitis B virus infection in the age of molecular biology? J Med Virol 80:974–979PubMedCrossRef

29.

Zhou B, Liu M, Lv G (2013) Quantification of hepatitis B surface antigen and E antigen: correlation between Elecsys and architect assays. J Viral Hepat 20(6):422–429PubMedCrossRef

30.

Wursthorn K, Jaroszewicz J, Zacher BJ (2011) Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. J Clin Virol 50(4):292–296PubMedCrossRef

31.

Sonneveld MJ, Rijckborst V, Boucher CA (2011) A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B. J Clin Virol 51(3):175–178PubMedCrossRef

32.

Maylin S, Boyd A, Delaugerre C (2012) Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus. Clin Vaccine Immunol 19(2):242–248PubMedCentralPubMedCrossRef

33.

Verheyen J, Neumann-Fraune M, Berg T (2012) The detection of HBsAg mutants expressed in vitro using two different quantitative HBsAg assays. J Clin Virol 54(3):279–281PubMedCrossRef

34.

Lee JM, Ahn SH, Chang HY (2004) Reappraisal of HBV genotypes and clinical significance in Koreans using MALDI-TOF mass spectrometry. Korean J Hepatol 10:260–270PubMed

35.

Bae SH, Yoon SK, Jang JW (2005) Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J Korean Med Sci 20:816–820PubMedCentralPubMedCrossRef

36.

Song BC, Cui XJ, Kim HU, Cho YK (2006) Sequential accumulation of the basal core promoter and the precore mutations in the progression of hepatitis B virus-related chronic liver disease. Intervirology 49:266–273PubMedCrossRef

Titel: Comparison of two immunoassays for quantification of hepatitis B surface antigen in Chinese patients with concomitant hepatitis B surface antigen and hepatitis B surface antibodies
verfasst von: Weiwei Liu
Yao Hu
Yannan Yang
Tingting Hu
Xinyu Wang
Publikationsdatum: 01.01.2015
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 1/2015
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-014-2253-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Identification of several clades of novel single-stranded circular DNA viruses with conserved stem-loop structures in pig feces

Multiplex PCR assay for the rapid identification of human papillomavirus genotypes 16, 18, 45, 35, 66, 33, 51, 58, and 31 in clinical samples

Hepatitis E virus genotypes 1 and 3 in wastewater samples in Tunisia

Pathophysiology of the pancreas after oral infection of genetically diverse mice with coxsackievirus B4-E2

Detection and molecular characterization of bovine leukemia virus in Philippine cattle